EP1519933A1 - Derives d'amides quinuclidine - Google Patents

Derives d'amides quinuclidine

Info

Publication number
EP1519933A1
EP1519933A1 EP03762514A EP03762514A EP1519933A1 EP 1519933 A1 EP1519933 A1 EP 1519933A1 EP 03762514 A EP03762514 A EP 03762514A EP 03762514 A EP03762514 A EP 03762514A EP 1519933 A1 EP1519933 A1 EP 1519933A1
Authority
EP
European Patent Office
Prior art keywords
hydroxy
azoniabicyclo
group
octane
azabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP03762514A
Other languages
German (de)
English (en)
Other versions
EP1519933B1 (fr
Inventor
Maria Prat Quinones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma AG filed Critical Almirall Prodesfarma AG
Publication of EP1519933A1 publication Critical patent/EP1519933A1/fr
Application granted granted Critical
Publication of EP1519933B1 publication Critical patent/EP1519933B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Definitions

  • This invention relates to new therapeutically useful quinuclidine amide derivatives, to some processes for their preparation and to pharmaceutical compositions containing them.
  • novel structures according to the invention are antimuscarinic agents with a potent and long lasting effect.
  • these compounds show high affinity for M3 muscarinic receptors.
  • This subtype of muscarinic receptor is present in glands and smooth muscle and mediates the excitatory effects of the parasympathetic system on glandular secretion and on the contraction of visceral smooth muscle (Chapter 6, Cholinergic Transmission, in HP. Rang et al., Pharmacology, Churchill Livingstone, New York , 1995).
  • M3 antagonists are therefore known to be useful for treating diseases characterised by an increased parasympathetic tone, by excessive glandular secretion or by smooth muscle contraction (R.M. Eglen and S.S. Hegde, (1997), Drug News Perspect., 10(8):462-469).
  • respiratory disorders such as chronic obstructive pulmonary disease (COPD), bronchitis, bronchial hyperreactivity, asthma, cough and rhinitis; urological disorders such as urinary incontinence, pollakiuria, neurogenic or unstable bladder, cystospasm and chronic cystitis; gastrointestinal disorders such as irritable bowel syndrome, spastic colitis, diverticulitis and peptic ulceration; and cardiovascular disorders such as vagally induced sinus bradycardia (Chapter 7, Muscarinic Receptor Agonists and Antagonists, in Goodman and Gilman's The
  • COPD chronic obstructive pulmonary disease
  • bronchitis bronchial hyperreactivity
  • asthma cough and rhinitis
  • urological disorders such as urinary incontinence, pollakiuria, neurogenic or unstable bladder, cystospasm and chronic cystitis
  • gastrointestinal disorders such as irritable bowel syndrome, spastic colitis, diverticulitis and peptic ulceration
  • the compounds of the invention can be used alone or in association with other drugs commonly regarded as effective in the treatment of these diseases.
  • they can be administered in combination with ⁇ 2 -agonists, steroids, antiallergic drugs, phosphodiesterase IV inhibitors and/or leukotriene D4 (LTD4) antagonists for simultaneous, separate or sequential use in the treatment of a respiratory disease.
  • ⁇ 2 -agonists steroids, antiallergic drugs, phosphodiesterase IV inhibitors and/or leukotriene D4 (LTD4) antagonists
  • Ri represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group
  • R 2 represents a group of formula i) or ii)
  • R 3 represents a group selected from phenyl, 2-furyl, 3-furyl, 2-thienyl or 3-thienyl;
  • R 4 represents a group selected from optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, cycloalkyl, cycioalkylmethyl, phenyl, benzyl, phenethyl, 2-furyl, 3-furyl, 2-thienyl or 3-thienyl;
  • R 5 represents a hydrogen atom or a hydroxy, methyl, or -CH 2 OH group
  • R 3 and R 4 being each independently optionally substituted by one, two or three substituents selected from halogen, straight or branched, optionally substituted lower alkyl, hydroxy, straight or branched, optionally substituted lower alkoxy, nitro, cyano, -CO 2 R' or - NR'R", wherein R' and R" each independently represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group or R' and R" together with the atom to which they are attached form a cyclic group;
  • p is 1 or 2 and the amide group is at positions 2, 3 or 4 of the azabicyclic ring;
  • R 5 when said compound is not a pharmaceutically acceptable salt or is a HCI salt, then R 5 cannot be one of hydrogen or hydroxy;
  • R 5 when said compound is a quaternary ammonium salt having a methyl group attached to the nitrogen atom of the quinuclidine ring, then R 5 cannot be hydroxy.
  • the compounds of the invention include quaternary ammonium salts of formula (II).
  • R-i, R 2 and p are as defined above;
  • n is an integer from 0 to 8.
  • n is an integer from 0 to 4:
  • X " represents a pharmaceutically acceptable anion of a mono or polyvalent acid
  • Further objectives of the present invention are to provide processes for preparing said compounds; pharmaceutical compositions comprising an effective amount of said compounds; the use of the compounds in the manufacture of a medicament for the treatment of diseases susceptible of being improved by antagonism of M3 muscarinic receptors; and methods of treatment of diseases susceptible to amelioration by antagonism of M3 muscarinic receptors, which methods comprise the administration of the compounds of the invention to a subject in need of treatment.
  • an alkyl group or moiety can be straight or branched, and is typically a lower alkyl group or moiety.
  • a lower alkyl group or moiety contains 1 to 8, preferably 1 to 6 and more preferably 1 to 4 carbon atoms.
  • such an alkyl group or moiety is represented by a methyl, ethyl, propyl, including i-propyl or butyl, including n-butyl, sec-butyl and tert-butyl group or moiety.
  • an alkenyl group or moiety can be straight or branched, and is typically a lower alkenyl group or moiety.
  • a lower alkenyl group or moiety contains 2 to 8, preferably 2 to 6 and more preferably 2 to 4 carbon atoms.
  • such an alkenyl group or moiety is represented by a vinyl, allyl or 1-propenyl group or moiety.
  • an alkynyl group or moiety can be straight or branched, and is typically a lower alkynyl group or moiety.
  • a lower alkynyl group or moiety contains 2 to 8, preferably 2 to 6 and more preferably 2 to 4 carbon atoms.
  • such an alkynyl group or moiety is represented by a 3-butynyl or 1-propynyl group or moiety.
  • Optionally substituted lower alkyl, alkenyl or alkynyl groups mentioned herein include straight or branched lower alkyl, alkenyl or alkynyl groups as defined above, which may be unsubstituted or substituted in any position by one or more substituents, for example by 1 , 2 or 3 substituents. When two or more substituents are present, each substituent may be the same or different.
  • the substituent(s) are typically halogen atoms, preferably fluoride atoms, and hydroxy or alkoxy groups.
  • Alkoxy groups mentioned herein are typically lower alkoxy groups, that is groups containing from 1 to 8, preferably 1 to 6 and more preferably 1 to 4 carbon atoms, the hydrocarbon chain being branched or straight and optionally substituted in any position by one or more substituents, for example by 1 , 2 or 3 substituents. When two or more substituents are present, each substituent may be the same or different.
  • the substituent(s) are typically halogen atoms, most preferably fluoride atoms, and hydroxy groups.
  • Preferred optionally substituted alkoxy groups include methoxy, ethoxy, n- propoxy, i-propoxy, n-butoxy, sec-butoxy, t-butoxy, trifluoromethoxy and difluoromethoxy, hydroxymethoxy, hydroxyethoxy or 2-hydroxypropoxy.
  • Cyclic groups mentioned herein include carbocydic and heterocyclic groups.
  • the cyclic groups can contain one or more rings.
  • Carbocydic groups may be aromatic or alicyclic, for example cycloalkyl groups.
  • Heterocyclic groups also include heteroaryl groups.
  • aromatic group typically contains from 5 to 14, preferably 5 to 10 carbon atoms.
  • aromatic groups include phenyl and naphthalenyl.
  • a heterocyclic or heteroaromatic group mentioned herein is typically a 5 to 10 membered group, such as a 5, 6 or 7 membered group, containing one or more heteroatoms selected from N, S and O. Typically, 1 , 2, 3 or 4 heteroatoms are present, preferably 1 or 2 heteroatoms.
  • a heterocyclic or heteroaromatic group may be a single ring or two or more fused rings wherein at least one ring contains a heteroatom.
  • heterocyclic groups include piperidyl, pyrrolidyl, piperazinyl, morpholinyl, thiomorpholinyl, pyrrolyl, imidazolyl, imidazolidinyl, pyrazolinyl, indolinyl, isoindolinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, quinuclidinyl, triazolyl, pyrazolyl, tetrazolyl, thienyl and dioxolyl.
  • heteroaromatic groups include pyridyl, thienyl, furyl, pyrrolyl, imidazolyl, benzothiazolyl, pyridinyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, triazolyl and pyrazolyl.
  • halogen atom includes a fluorine, chlorine, bromine or iodine atom, typically a fluorine, chlorine or bromine atom.
  • a pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base.
  • Pharmaceutically acceptable acids include both inorganic acids, for example hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic and nitric acid and organic acids, for example citric, fumaric, formic, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p- toluenesulphonic acid.
  • Pharmaceutically acceptable bases include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g.
  • Preferred salts of the compounds of formula (I) are those formed between the nitrogen atom of the azabicyclic ring and an inorganic or an organic acid
  • Other preferred salts according to the invention are quaternary ammonium compounds of formula (II), wherein an equivalent of an anion (X " )is associated with the positive charge of the N atom.
  • X " may be an anion of various mineral acids such as, for example, chloride, bromide, iodide, sulphate, nitrate, phosphate, or an anion of an organic acid such as, for example, acetate, formate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, trifluoroacetate, methanesulphonate and p-toluenesulphonate.
  • X " is preferably an anion selected from chloride, bromide, iodide, sulphate, nitrate, acetate, maleate, oxalate, succinate or trifluoroacetate. More preferably X ' is chloride, bromide, trifluoroacetate or methanesulphonate.
  • Preferred compounds of formulae (I) or (II) are those wherein Ri is hydrogen, methyl or ethyl, most preferably hydrogen.
  • R 2 is a group of formula i), wherein R 3 is a group, which is optionally substituted with one or more halogen atom(s), selected from phenyl, 2-thienyl, 3-thienyl or 2-furyl. More preferably R 2 is a group of formula i), wherein R 3 represents a group phenyl, 2-thienyl or 2-furyl which are optionally substituted with one or more halogen atom(s). Most preferably, R 3 is phenyl or 2-thienyl,
  • R 4 represents a linear group selected from ethyl, n-butyl, vinyl, allyl, 1-propenyl and 1- propynyl, or a group, which is optionally substituted with one or more halogen atom(s), methyl or methoxy group(s), selected from cyclopentyl, cyclohexyl, phenyl, benzyl, phenethyl, 2-thienyl and 3-furyl.
  • compounds having a group of formula i) are those wherein R 4 represents a linear group selected from ethyl, n-butyl, vinyl, allyl and 1-propynyl, or a group, which is optionally substituted with one or more halogen atom(s), methyl or methoxy group(s), selected from cyclopentyl, phenyl, benzyl, phenethyl and 2- thienyl Most preferably, R 4 is ethyl, n-butyl, vinyl, allyl, cyclopentyl, phenyl, benzyl or 2- thienyl.
  • R 2 is a group of formula ii), wherein Q represents a single bond or an oxygen atom. ln the most preferred embodiments of the invention R 5 in groups i) or ii) is a hydrogen atom or a hydroxy group.
  • p is 2 and the amide group is at positions 3 or 4 of the azabicyclic ring, most preferably at position 3.
  • -C 4 alkyl group which is optionally substituted with one or more halogen atom(s), a straight C 1 -C 4 alkoxy group, which is optionally substituted with one or more halogen atom(s) or hydroxy group(s), or a cyclic group, which is optionally substituted with one or more substituents selected from halogen atoms, groups of formula -C(O)NR'R" or methyl, hydroxy, nitro or phenyl groups, the cyclic group being selected from cyclohexyl, phenyl, 5,6,7,8-tetrahydronaphthanelyl, 2- thienyl, 1-pyrrolidinyl, 1 -pyrrolyl, benzo[1 ,3]dioxolyl, 2-benzothiazolyl, naphthalenyl and dioxolyl.
  • compounds of formula (II) are those wherein m is an integer from 0 to 5 and n is an integer from 0 to 2;
  • R 6 - (CH 2 ) n - A - (CH 2 ) m - is one of methyl, 3-phenoxypropyl, 3-(3-hydroxyphenoxy)propyI, allyl, heptyl, 3- phenylpropyl, 3-phenylallyl, 2-phenoxyethyl, 2-benzyloxyethyl, cyclohexylmethyl, 3- (5,6,7,8-tetrahydronaphthalen-2-yloxy)propyl, 5-(2,6-dimethylphenoxy)pentyl, 3-thien-2- ylpropyl or 3-cyclohexylpropyl and X " is bromide or trifluoroacetate.
  • the compounds of the present invention represented by formulae (I) or (II) described above may have one or more asymmetric atoms, e.g. the carbon in position 3 of the quinuclidine ring; the carbon substituted by R 3 , R 4 and R 5 in the compounds wherein R 2 is a group of formula i); or the carbon which is attached to the carbonyl group in the compounds wherein R 2 is a group of formula ii).
  • asymmetric atoms may have R- or S-configuration.
  • the single isomers and mixtures of the isomers fall within the scope of the invention.
  • Particular individual compounds of formula (I) include:
  • Particular individual compounds of formula (II) include:
  • the present invention provides processes for preparing the novel quinuclidine amide derivatives of formulae (I) and (II)
  • the compounds of formula (I) may be prepared from the corresponding carboxylic acid of formula (III) following two different methods (a) and (b), illustrated in the following scheme.
  • Some compounds of formula (IV) are commercially available, for example 3- aminoquinuclidine (Aldrich, dihydrochloride) , (3R)-aminoquinuclidine (Aldrich, Finorga, dihydrochloride) and (3S)-aminoquinuclidine (Aldrich, dihydrochloride).
  • (3R)-N-methylquinuclidin-3-amine has been prepared as described in the experimental section.
  • the compounds of formula (V) may be prepared from the corresponding glyoxylic acids following methods equivalent to methods (a) and (b) described in Scheme 1
  • the quaternary ammonium derivatives of formula (II) may be prepared, as illustrated in the following scheme, by reaction of the compounds of formula (I) with an alkylating agent of formula (VI) using two possible methods -(d) or (e)-, described in detail in the experimental section.
  • Method (e) involves the use of solid phase extraction techniques that allow the parallel preparation of several compounds.
  • W represents any suitable leaving group, preferably a group X " as defined above for the compounds of formula (II).
  • W is a leaving group other than X "
  • the quaternary ammonium salt of formula (II) is produced from the product of method (d) or (e) by an exchange reaction according to standard methods to replace the anion W " with the desired anion X " .
  • the compounds of formulae (I) and (II) can have one or more asymmetric carbons. All possible stereoisomers, single isomers and mixtures of isomers are also included within the scope of the present invention.
  • the diastereomers of the compounds may be separated by conventional methods, for example by chromatography or crystallisation.
  • the structures of the compounds were confirmed by 1 H-NMR and MS.
  • the NMR spectra were recorded using either a Varian 300 MHz instrument or a Bruker DPX-250 instrument. Chemical shifts are expressed as parts per million ( ⁇ ) from the internal reference tetramethylsilane.
  • the purity of the compounds was determined by HPLC, using reverse phase chromatography on a Waters instrument. Molecular ions were produced by electrospray ionisation mass spectrometry on a Hewlett Packard instrument.
  • Oxalyl chloride (0.540 ml, 0.0062 mol) was added to a solution of 9H-xanthene-9- carboxylic acid (1.16 g, 0.0051 mol) and dimethylformamide (two drops) in 20 ml of CHCI 3 (ethanol free) at 0°C. The mixture was allowed to warm to room temperature under stirring and maintained 1 h at this temperature. After this time, the reaction mixture was concentrated to dryness in vacuo and the obtained residue was dissolved in CHCI 3 (15 ml) and concentrated again. This procedure was repeated two times. The obtained residue was dissolved in CHCI 3 and the solution cooled to 0°C.
  • N-(1 -Azabicyclo[2.2.2]oct-3-yl)-9H-xanthene-9-carboxamide (Example 28) N-[(3R)-1 -Azabicyclo[2.2.2]oct-3-yl]-9H-xanthene-9-carboxamide (Example 31 ) N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-9H-xanthene-9-carboxamide (Example 33) All three from 9H-xanthene-9 carboxylic acid.
  • 2,2-dithien-2-ylacetic acid was produced by hydrolysis of 2,2-dithien-2-ylacetic acid methyl ester, previously prepared as described in F. Leonard and I. Ehranthal, J. Am. Chem. Soc, (1951), Vol 73, pag 2216.
  • 1.2 g (0.0054 mol) of 2,2-dithien-2-ylacetic acid were dissolved in 25 ml of THF.
  • 0.96 g (0.00594 mol) of 1 , 1 ' - carbonyldiimidazole was refluxed for an hour. The reaction was monitored by TLC following the formation of the imidazolide.
  • the title compound was prepared as is described in Example 44 starting from (2S)-2- Cyclopentyl-2-hydroxy-2-thien-2-yl acetic acid .
  • the obtained product was purified by column chromatography (silica gel, CHCI 3 : MeOH: NH 4 OH 99:1 :1 - CHCI 3 : MeOH:NH 4 OH 97:3:1 as eluent) to give 800 mg of the title product impurified with imidazole.
  • the obtained product was dissolved in CHCI 3 and washed with H 2 O (x 3). The organic solution was dried over Na 2 SO 4 , filtered and concentrated in vacuo to yield 650 mg of the title product (44% from the starting acid). Structure confirmed by 1 H-RMN and MS.
  • Oxalyl chloride (4.5 ml, 0.0516 mol) was added to a solution of 6.68 g (0.0428 mol) of 2- oxo-2-thien-2-ylacetic acid and DMF (several drops) in 100 ml of CHCI 3 (ethanol free) at 0°C. The mixture was stirred and allowed to warm to room temperature. After two hours at this temperature, the solvents were evaporated and the residue was dissolved in CHCI 3 and evaporated again. This procedure was repeated two times. The oil obtained was dissolved in CHCi 3 and the solution obtained cooled at 0°C. A solution of (3R)- aminoquinuclidine (5.91 g, 0.0468 mol) in 50 ml of CHCI 3 was added.
  • a solution of 2-thienylmagnesium bromide was prepared from 2.27 g (0.094 mol) of magnesium and 15.4 g (0.094 mol) of 2-bromothiophene in 150 ml of THF. This solution was added to a solution of 11.34 g (0.043 mol) of N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-2- oxo-2-thien-2-ylacetamide (Intermediate 1-1) in 120 ml of THF. The mixture was stirred at room temperature for one hour, refluxed for one hour, cooled and treated with a saturated solution of ammonium chloride.
  • the solution obtained was basified with a K 2 CO 3 solution and extracted with CH 2 CI 2 .
  • the organic layer was washed with water and brine, dried over Na 2 SO 4 and treated with activated carbon.
  • the solution obtained was filtered trough Celite and solvents were evaporated to give a solid that was treated with ether and filtered to give 8.77 (58.5%) of the title product. . m.
  • Diastereomer 1 first diastereomer obtained
  • Diastereomer 2 second distereomer obtained.
  • the obtained product was dissolved in dry THF (45 ml).
  • the solution obtained was cooled to -80°C and 14.4 ml of a 1M solution in THF of 4-fluoro-3-methylphenylmagnesium bromide (0.014 mol) were added.
  • the mixture was stirred during 3 hours at low temperature. After this time, the reaction mixture was treated with NH 4 CI (saturated solution) and extracted with AcOEt. The organic layer was dried over Na 2 S0 4 , filtered and solvents were evaporated.
  • 2-(5-bromothien-2-yl)-2-oxoacetic acid was obtained by hydrolysis of ethyl 2-(5- bromothien-2-yl)-2-oxoacetate by a standard method (EtOH, NaOH 2N, 60°C, 1.5 h).
  • the obtained product was dissolved in CHCI 3 (50 ml), the solution was cooled to 0°C and 1.7 g (0.013 mol) of (3R)-aminoquinuclidine were added. The mixture was allowed to warm to room temperature and continued stirring during 16 hours. After this time the reaction mixture was treated with K 2 CO 3 (saturated solution) and the aqueous layer was extracted with CH 2 CI 2 . The organic layers were combined, washed with water, dried over Na 2 SO 4 , filtered and evaporated. The obtained product (N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-(2- furyl)-2-oxoacetamide) was used without further purification as is described as follows.
  • compositions which comprise, as the active ingredient, at least one quinuclidine amide derivative of formulae (I) or (II) in association with a pharmaceutically acceptable carrier or diluent.
  • a pharmaceutically acceptable carrier or diluent Preferably the composition is made up in a form suitable for oral administration.
  • composition of this invention The pharmaceutically acceptable carrier or diluents which are mixed with the active compound or compounds, to form the composition of this invention are well-known per se and the actual excipients used depend inter alia on the intended method of administration of the composition.
  • compositions of this invention are preferably adapted for oral administration.
  • the composition for oral administration may take the form of tablets, film-coated tablets, liquid inhalant, powder inhalant and inhalation aerosol; all containing one or more compounds of the invention; such preparations may be made by methods well-known in the art.
  • the diluents which may be used in the preparations of the compositions include those liquid and solid diluents which are compatible with the active ingredient, together with colouring or flavouring agents, if desired.
  • Tablets or film-coated tablets may conveniently contain between 1 and 500 mg, preferably from 5 to 300 mg of active ingredient.
  • the inhalant compositions may contain between 1 ⁇ g and 1 ,000 ⁇ g, preferably from 10 ⁇ g to 800 ⁇ g of active ingredient.
  • the dose of the compound of formulae (I) or (II) depend on the desired effect and duration of treatment; adult doses are generally between 3 mg and 300 mg per day as tablets and 10 ⁇ g and 800 ⁇ g per day as inhalant composition.
  • membrane preparations were suspended in DPBS to a final concentration of 89 ⁇ g/ml for the M3 subtype. The membrane suspension was incubated with the tritiated compound for 60 min. After incubation the membrane fraction was separated by filtration and the bound radioactivity determined. Non-specific binding was determined by addition of 10 "4 M atropine. At least six concentrations were assayed in duplicate to generate individual displacement curves.
  • the compounds of the present invention have high affinities for M3 muscarinic receptors, preferably human muscarinic receptors.
  • the IC 50 of the preferred compounds of the invention is lower than 100 nM.
  • the compounds of the present invention inhibited the bronchospasm response to acetylcholine with high potency and a long duration of action.
  • the compounds of the present invention have excellent M3 antimuscarinic activity and thus are useful for the treatment of diseases in which the M3 muscarinic receptor is implicated, including respiratory disorders such as chronic obstructive pulmonary disease (COPD), bronchitis, bronchial hyperreactivity, asthma, cough and rhinitis; urological disorders such as urinary incontinence, pollakiuria, neurogenic or unstable bladder, cystospasm and chronic cystitis; gastrointestinal disorders such as irritable bowel syndrome, spastic colitis, diverticulitis and peptic ulceration; and cardiovascular disorders such as vagally induced sinus bradycardia.
  • COPD chronic obstructive pulmonary disease
  • bronchitis bronchial hyperreactivity
  • asthma cough and rhinitis
  • urological disorders such as urinary incontinence, pollakiuria, neurogenic or unstable bladder, cystospasm and chronic cystitis
  • gastrointestinal disorders such as irritable bowel syndrome, spastic co
  • the present invention further provides a compound of formulae (I) or (II) or a pharmaceutically acceptable composition comprising a compound of formulae (I) or (II) for use in a method of treatment of the human or animal body by therapy, in particular for the treatment of respiratory, urological or gastrointestinal disease or disorder.
  • the present invention further provides the use of a compound of formulae (I) or (II) or a pharmaceutically acceptable composition comprising a compound of formulae (I) or (II) for the manufacture of a medicament for the treatment of a respiratory, urological or gastrointestinal disease or disorder.
  • the compounds of formulae (I) or (II) and pharmaceutical compositions comprising a compound of formulae (I) or (II) can be used in a method of treating a respiratory, urological or gastrointestinal disease or disorder, which method comprises administering to a human or animal patient in need of such treatment an effective, non- toxic, amount of a compound of formulae (I) or (II) or a pharmaceutical composition comprising a compound of formulae (I) or (II).
  • the compounds of formulae (I) or (II) and pharmaceutical compositions comprising a compound of formulae (I) or (II) can be used in combination with other drugs effective in the treatment of these diseases.
  • drugs effective in the treatment of these diseases.
  • ⁇ 2 agonists steroids, antiallergic drugs, phosphodiesterase IV inhibitors and/or leukotriene D4 (LTD4) inhibitors, for simultaneous, separate or sequential use in the treatment of a respiratory disease.
  • steroids for example with ⁇ 2 agonists, steroids, antiallergic drugs, phosphodiesterase IV inhibitors and/or leukotriene D4 (LTD4) inhibitors, for simultaneous, separate or sequential use in the treatment of a respiratory disease.
  • antiallergic drugs phosphodiesterase IV inhibitors
  • LTD4 leukotriene D4
  • the title compound was synthesised according to methods c and e.
  • the yield of the final step was 0.0124 g, 30.2%.
  • the title compound was synthesised according to methods c and e.
  • the yield of the final step was 0.010 g, 23.1 %.
  • the title compound was synthesised as a mixture of diastereomers according to method a.
  • the yield was 1.21 g, 82.3 %. m.p.: 142°C.
  • the title compound was synthesised as a mixture of diastereomers according to method b.
  • the yield was 0.25 g, 28.4 %. m.p.: 69.8-73.3°C.
  • the title compound was synthesised as a mixture of diastereomers according to method a.
  • the yield was 1.59 g, 63.1 %. m.p.: 136°C.
  • the title compound was also synthesised according to method a.
  • the yield was 2.11 g, 52.6 %.
  • the title compound was synthesised according to methods a and d.
  • the yield of the final step was 0.25 g, 77.6%. m.p.: 318°C.
  • the title compound was synthesised according to methods a and d.
  • the yield of the final step was 0.48 g, 98%. m.p.: 278.5-279.2°C.
  • the title compound was synthesised according to method a.
  • the yield was 1.1 g, 60%. m.p.: 244.2-244.9°C.
  • the title compound was synthesised according to methods a and e.
  • the yield of the final step was 0.0091 g, 22.1%.
  • the title compound was synthesised according to methods a and e.
  • the yield of the final step was 0.0124 g, 27.0 %.
  • ⁇ -RMN (CDCI 3 ): (mixture of diastereomers) ⁇ 7.36 - 7.35 (m, 1 H), 6.87 - 6.76 (m, NH, 1 H), 6.54 - 6.52 (m, 1 H), 6.34 - 6.32 (m, 1 H), 3.92 (m, 1H), 3.29 - 3.17 (m, 1 H), 2.78 - 2.64 (m, 4H), 2.47 - 2.35 (m, 1 H), 2.00 - 1.90 (m, 1 H), 1.92 (s, 3H), 1.70 - 1.39 (m, 4H).
  • the title compound was synthesized as a mixture of diastereomers according to methods c and d.
  • the reaction time for the final step (conditions:THF, reflux temperature) was 7 days.
  • the obtained product was purified by several washings with ether .
  • the yield was 0.337 g (75%).
  • the title compound was synthesized as a mixture of diastereomers according to methods c an d.
  • the reaction time for the final step (conditions, THF, reflux temperature) was 7 days.
  • the obtained product was purified by several washings with ether.
  • the yield was 0.252 g
  • the title compound was synthesised as a mixture of diastereomers according to methods c and d.
  • the reaction time for the final step (conditions, THF, reflux temperature) was 2 days.
  • the obtained product was purified by several washings with ether.
  • the yield was 0.320 g
  • the title compound was synthesised as a mixture of diastereomers according to methods c and d.
  • the reaction time for the final step (conditions: THF, reflux temperature) was 46 hours.
  • the obtained product was purified by several washings with ether. The yield was 0.201 g (92%).
  • Titanium dioxide 1.1 mg Purified talc 0.7 mg
  • a coating solution was prepared by suspending 6.9 g of hydroxypropylmethylcellulose 2910, 1.2 g of polyethylene glycol 6000, 3.3 g of titanium dioxide and 2.1 g of purified talc in 72.6 g of water. Using a High Coated, the 3,000 tablets prepared above were coated with the coating solution to give film-coated tablets, each having 154.5 mg in weight.
  • a 40 mg portion of the compound of the present invention was dissolved in 90 ml of physiological saline, and the solution was adjusted to a total volume of 100 ml with the same saline solution, dispensed in 1 ml portions into 1 ml capacity ampoule and then sterilized at 115 °C for 30 minutes to give a liquid inhalant.
  • a 20 g portion of the compound of the present invention was uniformly mixed with 400 g of lactose, and a 200 mg portion of the mixture was packed in a powder inhaler for exclusive use to produce a powder inhalant.
  • Example 66 Preparation of a pharmaceutical composition: inhalation aerosol.
  • the active ingredient concentrate is prepared by dissolving 0.0480 g of the compound of the present invention in 2.0160 g of ethyl alcohol. The concentrate is added to an appropriate filling apparatus. The active ingredient concentrate is dispensed into aerosol container, the headspace of the container is purged with Nitrogen or HFC-134A vapour (purging ingredients should not contain more than 1 ppm oxygen) and is sealed with valve. 11.2344 g of HFC-134A propellant is then pressure filled into the sealed container.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouveaux dérivés de quinuclidine amide de structure chimique correspondant à la formule générale (I), ainsi que leurs sels pharmaceutiquement compatibles, y compris les sels quaternaires de formule (II). L'invention concerne en outre des procédés de préparation de ces dérivés, des compositions pharmaceutiques les renfermant et leur utilisation en thérapie, comme antagonistes de récepteurs muscariniques M3.
EP03762514A 2002-07-02 2003-06-25 Derives d'amides quinuclidine Expired - Lifetime EP1519933B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200201539P 2002-07-02
ES200201539A ES2204295B1 (es) 2002-07-02 2002-07-02 Nuevos derivados de quinuclidina-amida.
PCT/EP2003/006708 WO2004005285A1 (fr) 2002-07-02 2003-06-25 Derives de quinuclidine amide

Publications (2)

Publication Number Publication Date
EP1519933A1 true EP1519933A1 (fr) 2005-04-06
EP1519933B1 EP1519933B1 (fr) 2010-05-12

Family

ID=30011350

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03762514A Expired - Lifetime EP1519933B1 (fr) 2002-07-02 2003-06-25 Derives d'amides quinuclidine

Country Status (24)

Country Link
US (2) US7488735B2 (fr)
EP (1) EP1519933B1 (fr)
JP (1) JP2005533826A (fr)
CN (1) CN100404533C (fr)
AR (1) AR040351A1 (fr)
AT (1) ATE467631T1 (fr)
AU (1) AU2003242757B2 (fr)
BR (1) BR0312216A (fr)
CA (1) CA2492535A1 (fr)
DE (1) DE60332534D1 (fr)
EC (1) ECSP045519A (fr)
ES (1) ES2204295B1 (fr)
IL (1) IL165923A (fr)
MX (1) MXPA04012271A (fr)
MY (1) MY130803A (fr)
NO (1) NO20050164L (fr)
NZ (1) NZ537341A (fr)
PE (1) PE20040644A1 (fr)
RU (1) RU2314306C2 (fr)
TW (1) TW200402420A (fr)
UA (1) UA80832C2 (fr)
UY (1) UY27870A1 (fr)
WO (1) WO2004005285A1 (fr)
ZA (1) ZA200410404B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1345937B1 (fr) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Derives de carbamate quinuclidine et leur utilisation comme antagonistes m3
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
TWI363759B (en) * 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005112644A2 (fr) * 2004-05-13 2005-12-01 Glaxo Group Limited Antagonistes récepteurs d'acétyle choline muscarinique
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
DE602004027555D1 (de) * 2004-09-15 2010-07-15 Shuqiang Zhao Chinuclidinverbindungen mit quaternärer ammoniumgruppe, verfahren zu ihrer herstellung und ihre verwendung als acetylcholinblockierende mittel
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2625664C (fr) 2005-10-21 2016-01-05 Novartis Ag Molecules organiques
US9088384B2 (en) * 2005-10-27 2015-07-21 Qualcomm Incorporated Pilot symbol transmission in wireless communication systems
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
CA2664378A1 (fr) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines utilisees comme inhibiteurs des lipides kinases pl3k
AU2007342223B2 (en) 2007-01-10 2011-02-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
ES2554646T3 (es) * 2007-02-23 2015-12-22 Theravance Biopharma R&D Ip, Llc Compuestos de difenilmetilo de amonio cuaternario, de utilidad como antagonistas de receptores muscarínicos
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
MX2010006421A (es) 2007-12-10 2010-06-25 Novartis Ag Compuestos organicos.
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
WO2009098455A1 (fr) * 2008-02-06 2009-08-13 Astrazeneca Ab Dérivés de 2- (9h-xanthène-9-yl) -oxazol comme antagonistes du récepteur muscarinique m3 destinés au traitement de l'asthme et d'une maladie pulmonaire obstructive chronique
WO2009098453A1 (fr) * 2008-02-06 2009-08-13 Astrazeneca Ab Azonia bicycloalcanes comme antagonistes du récepteur d'acétylcholine muscarinique m3
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
EP2300010B1 (fr) 2008-06-10 2015-03-04 Novartis AG Dérivés de pyrazine en tant que bloqueur du canal sodique epithelial
GB0814728D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
MX2011001577A (es) * 2008-08-12 2011-05-02 Pulmagen Therapeutics Synergy Sal de 2-hidroxi-etansulfonato.
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (fr) 2009-08-12 2011-02-17 Novartis Ag Composes hydrazone heterocycliques et leurs utilisations pour traiter le cancer et l'inflammation
IN2012DN01961A (fr) 2009-08-17 2015-08-21 Intellikine Llc
EP2467383A1 (fr) 2009-08-20 2012-06-27 Novartis AG Composés d'oximes hétérocycliques
WO2011050325A1 (fr) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions destinées au traitement de la mucoviscidose et d'autres maladies chroniques
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (fr) 2011-02-10 2013-12-18 Novartis AG Composés de [1, 2, 4]triazolo [4, 3 -b]pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
SG192795A1 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as trk inhibitors
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
EP2702041A1 (fr) * 2011-04-29 2014-03-05 Chiesi Farmaceutici S.p.A. Dérivés d'alcaloïde ester et carbamate, et compositions médicinales à base de ceux-ci
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
WO2013038390A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Hétérocyclyle carboxamides n-substitués
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
WO2013038378A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyridinamides
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
RU2660354C2 (ru) 2012-04-03 2018-07-05 Новартис Аг Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (fr) 2013-03-15 2014-09-25 Intellikine, Llc Combinaison d'inhibiteurs de kinase et ses utilisations
JP6218940B2 (ja) * 2013-07-13 2017-10-25 ベイジン エフエスウェルカム テクノロジー ディベロップメント カンパニー リミテッド キニン系化合物、その光学異性体及びその製造方法と医薬用途
WO2015084804A1 (fr) 2013-12-03 2015-06-11 Novartis Ag Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
PT3134396T (pt) 2014-04-24 2019-12-16 Novartis Ag Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase
KR20160141855A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피라진 유도체
PL3134395T3 (pl) 2014-04-24 2018-07-31 Novartis Ag Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
BR112016028081A2 (pt) * 2014-05-30 2017-08-22 Sphaera Pharma Private Ltd Novos compostos como agentes antituberculares
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
CN107207510B (zh) 2014-07-31 2019-11-29 诺华股份有限公司 联合疗法
CN113891744A (zh) 2019-06-10 2022-01-04 诺华股份有限公司 用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物
KR20220052934A (ko) 2019-08-28 2022-04-28 노파르티스 아게 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도
CN110759904B (zh) * 2019-10-21 2023-03-14 河南科技大学 9r-酰氧基奎宁类衍生物及其制备方法、奎宁或其衍生物的应用、植物源杀虫剂
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2762796A (en) * 1956-09-11 Iminodibenzyl derivative
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
GB1246606A (en) 1969-04-28 1971-09-15 Starogardzkie Zakl Farma Dibenzo-azepine derivatives
IL72788A (en) 1984-08-28 1989-07-31 Israel State Bis quaternary oxy-bis methylene(or trimethylene)bis-n-quinuclidines,pyridines and piperidines,their preparation and antidotes against organophosphorus and carbamate poisoning containing them
GB2225574B (en) 1987-12-24 1991-04-24 Wyeth John & Brother Ltd Heterocyclic compounds
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
GB9201751D0 (en) 1992-01-28 1992-03-11 Smithkline Beecham Plc Compounds
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
EP0747355A4 (fr) 1994-02-10 1997-04-09 Yamanouchi Pharma Co Ltd Nouveau derive du carbamate et composition correspondante
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US6130232A (en) * 1995-10-13 2000-10-10 Banyu Pharmaceutical Coaltd Substituted piperidine derivatives as muscarinic M3 receptor antagonists
AUPN862996A0 (en) 1996-03-13 1996-04-04 Fujisawa Pharmaceutical Co., Ltd. A novel substituted-acetamide compound
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2213703T5 (es) * 2000-06-27 2011-11-02 Laboratorios S.A.L.V.A.T., S.A. Carbamatos derivados de arilalquilaminas.
EP1345937B1 (fr) * 2000-12-22 2005-09-28 Almirall Prodesfarma AG Derives de carbamate quinuclidine et leur utilisation comme antagonistes m3
ES2266291T3 (es) * 2000-12-28 2007-03-01 Almirall Prodesfarma Ag Nuevos derivados de quinuclidina y composiciones medicinales que los contienen.
CN1832948B (zh) * 2001-12-20 2011-06-15 基耶西药品股份公司 1-烷基-1-氮*双环[2.2.2]辛烷氨基甲酸酯衍生物及其用作蕈毒碱受体拮抗剂的用途
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ATE378336T1 (de) * 2002-09-19 2007-11-15 Schering Corp Imidazopyridine als hemmstoffe cyclin abhängiger kinasen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004005285A1 *

Also Published As

Publication number Publication date
ES2204295B1 (es) 2005-08-01
AU2003242757A1 (en) 2004-01-23
UA80832C2 (en) 2007-11-12
US20080234316A1 (en) 2008-09-25
NZ537341A (en) 2006-04-28
PE20040644A1 (es) 2004-09-18
ECSP045519A (es) 2005-03-10
ZA200410404B (en) 2005-09-05
US20060167042A1 (en) 2006-07-27
BR0312216A (pt) 2005-04-12
ATE467631T1 (de) 2010-05-15
CA2492535A1 (fr) 2004-01-15
DE60332534D1 (de) 2010-06-24
MY130803A (en) 2007-07-31
AR040351A1 (es) 2005-03-30
ES2204295A1 (es) 2004-04-16
US7718670B2 (en) 2010-05-18
CN100404533C (zh) 2008-07-23
UY27870A1 (es) 2003-10-31
US7488735B2 (en) 2009-02-10
NO20050164L (no) 2005-04-04
RU2005102585A (ru) 2005-10-10
JP2005533826A (ja) 2005-11-10
CN1678610A (zh) 2005-10-05
EP1519933B1 (fr) 2010-05-12
RU2314306C2 (ru) 2008-01-10
MXPA04012271A (es) 2005-04-08
IL165923A (en) 2010-06-30
AU2003242757B2 (en) 2009-01-08
IL165923A0 (en) 2006-01-15
WO2004005285A1 (fr) 2004-01-15
TW200402420A (en) 2004-02-16

Similar Documents

Publication Publication Date Title
US7488735B2 (en) Quinuclidine amide derivatives
EP1345937B1 (fr) Derives de carbamate quinuclidine et leur utilisation comme antagonistes m3
US7192978B2 (en) Pyrrolidinium derivatives
RU2282629C2 (ru) Производные хинуклидина, способ их получения и фармацевтическая композиция на их основе
RU2382041C2 (ru) Новые сложные эфиры кватернизованного хинуклидина
US20090054480A1 (en) Novel quinuclidine carbamate derivatives and medicinal compositions containing the same
KR20050024450A (ko) 신규한 퀴누클리딘 아미드 유도체

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070370

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALMIRALL AG

17Q First examination report despatched

Effective date: 20080404

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LABORATORIOS ALMIRALL, S.A.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALMIRALL, S.A.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: ALMIRALL, S.A.

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60332534

Country of ref document: DE

Date of ref document: 20100624

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20100512

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100813

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100630

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100913

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1070370

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110228

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

26N No opposition filed

Effective date: 20110215

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20100812

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100630

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110101

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100712

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100812

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60332534

Country of ref document: DE

Effective date: 20110215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101113

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100812